+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 30Years +
All Genders
ID07197866

Open-Label Extension Trial to Evaluate the Safety and Tolerability of Oral TEV-56286 in Adults with Multiple System Atrophy

Led by Teva Branded Pharmaceutical Products R&D LLC · Updated on 2026-10-09

200

Participants Needed

41

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term safety and tolerability of TEV-56286, an oral drug, for adults with Multiple System Atrophy MSA. This Phase 2 trial aims to observe how well participants tolerate the medication over an extended period and to further describe its safety profile. The study is sponsored by Teva Branded Pharmaceutical Products R&D LLC and plans to include participants aged 30 and older. Participants in the trial will receive TEV-56286 orally throughout the study. This open-label extension trial follows up on a previous double-blind trial, focusing on continued treatment and monitoring. The total planned duration for participant involvement is approximately 100 weeks, allowing for long-term observation of safety and tolerability. During the study, participants will undergo regular assessments to monitor adverse events, vital signs, laboratory test results including hematology and chemistry, and 12-lead ECG measurements. Researchers will track any side effects and reasons for withdrawal throughout the 100-week period. The trial includes safety follow-up visits and aims to collect comprehensive data on the long-term effects of TEV-56286 in adults with MSA.

CONDITIONS

Brief Title

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Research Team

T

Teva U.S. Medical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here